Cargando…

MET and Small-Cell Lung Cancer

Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelsomino, Francesco, Rossi, Giulio, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276958/
https://www.ncbi.nlm.nih.gov/pubmed/25314153
http://dx.doi.org/10.3390/cancers6042100
_version_ 1782350325214085120
author Gelsomino, Francesco
Rossi, Giulio
Tiseo, Marcello
author_facet Gelsomino, Francesco
Rossi, Giulio
Tiseo, Marcello
author_sort Gelsomino, Francesco
collection PubMed
description Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.
format Online
Article
Text
id pubmed-4276958
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42769582015-01-15 MET and Small-Cell Lung Cancer Gelsomino, Francesco Rossi, Giulio Tiseo, Marcello Cancers (Basel) Review Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC. MDPI 2014-10-13 /pmc/articles/PMC4276958/ /pubmed/25314153 http://dx.doi.org/10.3390/cancers6042100 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gelsomino, Francesco
Rossi, Giulio
Tiseo, Marcello
MET and Small-Cell Lung Cancer
title MET and Small-Cell Lung Cancer
title_full MET and Small-Cell Lung Cancer
title_fullStr MET and Small-Cell Lung Cancer
title_full_unstemmed MET and Small-Cell Lung Cancer
title_short MET and Small-Cell Lung Cancer
title_sort met and small-cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276958/
https://www.ncbi.nlm.nih.gov/pubmed/25314153
http://dx.doi.org/10.3390/cancers6042100
work_keys_str_mv AT gelsominofrancesco metandsmallcelllungcancer
AT rossigiulio metandsmallcelllungcancer
AT tiseomarcello metandsmallcelllungcancer